P.3.c.008 Open-label over effectiveness of long-acting risperidone as maintenance therapy of bipolar and schizoaffective disorders

P. Castro-Loli; Antonio Benabarre; Anabel Martínez‐Arán; José Sánchez‐Moreno; Manel Salamero; Andréa Murru; Eduard Vieta

doi:10.1016/s0924-977x(08)70593-5

Related publications

Article2010

[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].

Antoni Benabarre, P Castro, José Sánchez‐Moreno, Anabel Martínez‐Arán, Manel Salamero, Andréa Murru, Carolina Franco, Eduard Vieta

Article2019

Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review

Isabella Pacchiarotti, Jari Tiihonen, Georgios D. Kotzalidis, Norma Verdolini, Andréa Murru, José Manuel Goikolea, Marc Valentí, Alberto Aedo, Eduard Vieta

Article2001

Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders

Eduard Vieta, José Manuel Goikolea, Bàrbara Corbella, Antonio Benabarre, María Reinares, G. Martínez, Antonio García Fernández, Francesc Colom, Anabel Martínez‐Arán

Article2000

Risperidone therapy in bipolar disorder: Results from a 6-month open-label study in Spain

Eduard Vieta, Antonio Benabarre, G. Martínez, Aranzazu Fernández-Martínez, Cristòbal Gastó

Article2020

P.404 Effectiveness of maintenance electroconvulsive therapy in relapse prevention of bipolar disorder

Gerard Anmella, Santiago Madero, M. Sagué, Marina Pont, A. Torres, Antonio Benabarre, Miquel Bioque, Eduard Vieta, Andréa Murru